Used in pharmaceutical research as a potent and selective inhibitor of the enzyme fibroblast activation protein (FAP), which is overexpressed in various solid tumors. Its primary application lies in oncology, particularly in the development of targeted cancer therapies and imaging agents. Due to its high specificity for FAP, it serves as a key component in antibody-drug conjugates (ADCs) and radiolabeled tracers for positron emission tomography (PET), enabling precise tumor detection and monitoring of disease progression. Additionally, it has shown promise in modulating the tumor microenvironment by inhibiting FAP-mediated extracellular matrix remodeling, potentially enhancing the efficacy of immunotherapies and chemotherapy. Its structural stability and bioavailability make it suitable for in vivo applications in preclinical models.